$148 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 35 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 65.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
TERN | Sell | TERNS PHARMACEUTICALS INC | $8,487,500 | -34.8% | 970,000 | -11.8% | 5.75% | -40.0% |
SNDX | Sell | SYNDAX PHARMACEUTICALS INC | $6,275,672 | -10.0% | 299,841 | -9.1% | 4.25% | -17.2% |
ISEE | Sell | IVERIC BIO INC | $5,171,400 | -24.2% | 131,454 | -53.1% | 3.50% | -30.3% |
Sell | VENTYX BIOSCIENCES INC | $4,832,030 | -30.8% | 147,318 | -29.3% | 3.27% | -36.4% | |
CBAY | Sell | CYMABAY THERAPEUTICS INC. COMMON STOCK | $4,708,500 | -38.5% | 430,000 | -51.1% | 3.19% | -43.5% |
ACRS | Sell | ACLARIS THERAPEUTICS | $1,261,946 | +28.0% | 121,692 | -0.1% | 0.86% | +17.8% |
SVRA | Sell | SAVARA INC | $633,054 | +63.1% | 198,139 | -0.4% | 0.43% | +50.0% |
KNTE | Exit | KINNATE BIOPHARMA INC | $0 | – | -5,000 | -100.0% | -0.02% | – |
KROS | Exit | KEROS THERAPEUTICS INC | $0 | – | -3,575 | -100.0% | -0.11% | – |
VKTX | Exit | VIKING THERAPEUTICS INC | $0 | – | -14,000 | -100.0% | -0.17% | – |
MRSN | Exit | MERSANA THERAPEUTICS INC | $0 | – | -60,000 | -100.0% | -0.18% | – |
HZNP | Exit | HORIZON THERAPEUTICS PLC | $0 | – | -6,000 | -100.0% | -0.48% | – |
PMVP | Exit | PMV PHARMACEUTICALS INC | $0 | – | -154,471 | -100.0% | -0.54% | – |
IOVA | Exit | IOVANCE BIOTHERAPEUTICS INC | $0 | – | -153,639 | -100.0% | -0.69% | – |
FDMT | Exit | 4D MOLECULAR THERAPEUTICS INC | $0 | – | -104,753 | -100.0% | -1.33% | – |
Exit | CELLDEX THERAPEUTICS INCput | $0 | – | -1,000 | -100.0% | -2.65% | – | |
Exit | IVERIC BIO INCcall | $0 | – | -1,500 | -100.0% | -2.69% | – | |
SRPT | Exit | SAREPTA TEHRAPEUTICS INC | $0 | – | -32,770 | -100.0% | -3.33% | – |
BLU | Exit | BELLUS HEALTH INC | $0 | – | -632,500 | -100.0% | -3.36% | – |
UTHR | Exit | UNITED THERAPEUTICS CORP DEL | $0 | – | -23,500 | -100.0% | -3.88% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
IRIDEX CORP | 20 | Q3 2019 | 8.1% |
ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
VERACYTE INC | 19 | Q3 2019 | 10.1% |
ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
SC 13G/A | 2023-02-14 |
SC 13G/A | 2023-02-14 |
SC 13G/A | 2023-02-14 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.